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To the Editor: We read the letter from Hemkens et al. with
interest [1]. We find it flawed with respect to scientific
method, as well as inappropriate in its suggestion of a
potentially more detailed statistical method. First, we need
to comment that in our analysis we have taken the highest
level of evidence available for the relationship between
malignancy and use of insulin glargine (A21Gly, B31Arg,
B32Arg human insulin), randomised controlled trials, and
put it in the public domain. In our article, we observe (but
do not interpret) the data, and only state that the use of
insulin glargine in the circumstances of the studies included
is not associated with any reduction or increase in
malignancy rates.
The most fundamental error in the letter of Hemkens et al.
[1] is that the main argument is based on the position that
there is some probability that the use of insulin glargine
increases the rate of cancer. If this was the case then there
would be a hypothesis, however weak, to test. Such a
hypothesis cannot be drawn from a series of papers on a
possible increased risk of cancer linked with the use of
insulin glargine published in Diabetologia [2–5], as has been
noted by other independent authorities [6–8]. The authors’
own exploratory analysis [3], suggesting some relationship
based on insulin dose, is evidently flawed, as was highlight-
ed in an editorial published in the Lancet by a senior clinical
trials' statistician [8]. That editorial also cautioned against the
more general use of population observational analyses due to
their unknown prescribing biases [8].
This is important because, with no overall prior
probability that the use of insulin glargine increases or
decreases malignancy rates, our own data cannot be
criticised for including or excluding any particular relative
risk (offering a ‘proof’), as the authors attempt to do in their
letter [1]. It is only possible to say that overall insulin
glargine is not likely to increase the malignancy rate by
more than 36% or reduce it more than 40%. In particular,
since there is no prior probability of direction of change, the
likelihood of any effect from insulin glargine clusters
around our central estimate of risk (risk reduction of 10%)
given that such a probability will have a close to normal
distribution over the group of studies we include.
Thisis now the strongest statement available for discussing
a potential increased risk of cancer (and hypothesis-setting for
further testing, if deemed necessary). In addition, as noted
above, this would be a stronger argument than the modified
probabilities arising from the observational data, which have
no direction of likelihood.
The authors of the letter [1] make a point of commenting
on our data on breast cancer. Their difficulty arises from
results on the use of insulin glargine vs no insulin (not other
insulins) in observational studies, which have been noted
by the authors of these studies themselves to be likely to be
subject to statistical and methodological uncertainties [3, 4].
It is of course likely that people with diabetes with other co-
existing illnesses will be more likely to use insulin and,
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hospitals, in which modern insulins are more likely to be
available for therapy. Again, we make no claim that our
data on breast cancer suggest any change in malignancy
risk but, equally obviously, it is important to put these data
in the public domain in the event that others use them for
the purposes of a meta-analysis.
We comprehensively discussed the limitations of our data,
pointing out, as do Hemkens and colleagues in their letter [1],
the problem of small numbers of events, which is partly due
to the short duration of many of the studies available.
However, the quality of these studies is high; commercial
studies are generally of high-conduct quality due to continu-
ing external inspection of investigators and a significant
probability of external review by national drug regulators.
In our opinion, Hemkens and colleagues are wrong in
suggestingalternativestatisticalapproachestocombiningdata
from different studies. We note that in their own study they
seem to apply statistical techniques to data regardless of the
validity of these approaches [3, 8, 9]. Suggesting the
application of tests of non-homogeneity to multiple studies
with very small numbers of events is wholly inappropriate—
non-homogeneity testing is simply not powerful enough to
be useful in this situation. Sensitivity analyses can be useful
(indeed we break down the data by type of diabetes and by
duration of study, showing that the findings are consistent),
but it is wrong to suggest their wider application when the
number of events is already marginal, as stochastic effects
a r el i k e l yt oa p p e a r .
There is no data discrepancy between our paper and the
short communication from Rosenstock and colleagues [10].
In that article, Rosenstock and colleagues explicitly
describe that 20 events were reported as serious adverse
events on insulin glargine (a relative risk reduction of 37%),
and we also report 20 such events. Table 2 of the article by
Rosenstock et al. [10] clearly presents both serious and
non-serious adverse events, as is made clear in the footnote
to the table.
We accept entirely that the observational data that we
presented in the article are weak, just as we note that the
observational study of Hemkens and colleagues on the
same topic is weak. We make no other claim than pointing
out that the data presented are consistent with our higher-
level data. We would have been correctly criticised for
having access to these observational data in the sanofi-
aventis database and not placing them in the public domain.
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